About 9% of men of reproductive age in the United States experience fertility problems. One of the many causes of male ...

Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, ...

The biological parents of a baby born to another couple because of an embryo mix-up in Florida are doing their best to navigate an “absolutely impossible situation,” their attorney said. Subscribe to ...

A Florida couple embroiled in an embryo mix-up will keep their infant after reaching a custody agreement with the baby’s biological parents. Subscribe to read this story ad-free Get unlimited access ...

The couple at the center of an embryo mix-up case involving a Seminole County fertility clinic will raise the baby girl the woman gave birth to in December even though it is not their biological child ...

In vivo embryo production efficiency in goats has been associated with several intrinsic and extrinsic factors (1). Breed, nutrition, gonadotropin dose and type ...

Hair, nails, and horns, all made up of keratin, are some of the hardest and most resilient structures in animals. Inside zebrafish cells, keratin plays a distinct role, giving them the strength they ...

The biological parents of a child at the center of a fertility embryo mix-up have been located. Still, an attorney for the couple raising the child said a transfer is not being planned or contemplated ...

A Florida couple who claimed a fertility clinic error led to the woman giving birth to a “non-Caucasian child” who was not related to them said they have ...

A Florida couple discovered their baby was not biologically theirs after an IVF embryo mix-up. The couple sued the fertility clinic and doctor after genetic testing confirmed they were not the ...

Between 280 and 200 million years ago, a group of animals evolved which would eventually give rise to mammals, including humans: the therapsids. They were first described more than 150 years ago, ...

AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it from ...